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The high incidence of cardiomyopathy in patients with hemosiderosis, particularly in transfusional iron overload, strongly
indicates that iron accumulation in the heart plays a major role in the process leading to heart failure. In this context, iron-
mediated generation of noxious reactive oxygen species is believed to be the most important pathogenetic mechanism determining
cardiomyocyte damage, the initiating event of a pathologic progression involving apoptosis, fibrosis, and ultimately cardiac
dysfunction. However, recent findings suggest that additional mechanisms involving subcellular organelles and inflammatory
mediators are important factors in the development of this disease. Moreover, excess iron can amplify the cardiotoxic effect of
other agents or events. Finally, subcellular misdistribution of iron within cardiomyocytes may represent an additional pathway
leading to cardiac injury. Recent advances in imaging techniques and chelators development remarkably improved cardiac iron
overload detection and treatment, respectively. However, increased understanding of the pathogenic mechanisms of iron overload
cardiomyopathy is needed to pave the way for the development of improved therapeutic strategies.
1. Introduction
Every cell living under aerobic conditions inevitably and
continuously produces reactive oxygen species (ROS), such
as anion superoxide (O
2
∙−) and its dismutation product
hydrogen peroxide (H
2
O
2
). Through the iron-catalyzed Fen-
ton reaction, these relatively harmless products are trans-
formed into the highly reactive hydroxyl radical that can
attack biological macromolecules and thereby lead to cell
and tissue damage if the cellular antioxidant defenses are
overwhelmed. At neutral pH most iron precipitates as iron
Fe(III) hydroxides; however, in biological environments (e.g.,
in the cell cytoplasm), Fe(III) can bind low molecular weight
compounds like citrate or ATP that are able to keep it
soluble but leave one or more iron ligands free to participate
in ROS formation [1]. Therefore, this so-called catalytic
iron plays an essential role in oxygen radical biochemistry.
Interestingly, iron-dependent oxidative injury is not depen-
dent only on the well-known damage that ROS cause to
biological macromolecules; a recent study has shown the role
of mismetallation, a process in which superoxide and H
2
O
2
oxidize Fe(II) to Fe(III) and thus displace it from many iron-
dependent enzymes that lose their functional capacity [2].
In fact, iron is also essential for a wide range of
vital cellular functions such as oxygen transport, energy
production, and cell division [1, 3]. For this reason, iron
homeostasis is strictly regulated at both the systemic and
cellular levels in order to keep iron protein-bound. In the
circulation, iron is safely transported by transferrin (Tf),
whose binding capacity is normally not fully saturated [4].
Body iron homeostasis is regulated by the interaction of
the liver-derived peptide hepcidin and its receptor, the iron
exporter ferroportin [3]. Hepcidin binding causes ferroportin
internalization and degradation, thereby halting iron efflux.
Hepcidin gene expression is controlled by many factors
[5], obviously including body iron levels; iron-mediated
regulation largely depends on the BMP/SMAD pathway
whose activation requires genes like HFE, hemojuvelin, and
transferrin receptor 2 (TfR2) that are inactivated in various
forms of hereditary hemochromatosis [6].
In the cell, iron regulatory proteins (IRP1 and IRP2)
are mRNA-binding proteins that control the synthesis of
Hindawi Publishing Corporation
Oxidative Medicine and Cellular Longevity
Volume 2015, Article ID 230182, 10 pages
http://dx.doi.org/10.1155/2015/230182
2 Oxidative Medicine and Cellular Longevity
proteins involved in iron uptake (transferrin receptor, TfR1,
and DMT1), storage (ferritin), release (ferroportin), and
utilization according to intracellular iron levels. This ele-
gant posttranscriptional mechanism regulates cellular iron
balance in order to keep the amount of iron in the redox-
active labile iron pool (LIP) low enough to limit toxicity but
sufficient for cellular needs [1, 7].
Since no biological mechanisms exist for the excretion
of excess iron and hence body iron stores tend to increase
with ageing, particularly in females after menopause [8], the
maintenance of iron levels within the physiological range
could prevent a variety of major diseases and promote
longevity [9], as suggested by the increased life span caused by
iron restriction in flies and nematodes [10]. Indeed, many of
the beneficial effects of polyphenols in these settings may be
related to their iron-binding capacity. Interventions aimed at
maintaining correct levels of iron (and other micronutrients)
in order to achieve healthy ageing and longevity have been
recently considered [11].
2. Molecular and Cellular
Mechanisms Underlying Iron-Dependent
Cardiac Damage
2.1. Iron and Reactive Oxygen Species Generation in the Heart.
All the cell types that constitute the heart may be susceptible
to ROS-induced damage, including endothelial cells [12, 13],
but in this review we will focus on cardiomyocytes that are
particularly susceptible to ROS-mediated damage. In fact,
on the one hand, given the heart’s high need of energy,
cardiomyocytes are rich in mitochondria and consume large
amounts of oxygen; on the other hand, cardiomyocytes have
low levels of antioxidant enzymes [14]. However, direct reac-
tion between oxygen and biomolecules is slow in the absence
of a catalyst, and iron is the more potent catalyst of oxidative
stress.Therefore, when LIP expansion occurs, oxidative stress
can affect cardiac functions. Increasing the synthesis of
ferritin, the cytosolic protein that safely stores iron, represents
a response to iron-mediated oxidative stress [15]. In the heart,
synthesis of ferritin, which is enriched in H subunit [16]
and sequestrates redox-active iron, is at the basis of an iron-
based mechanism of ischemic preconditioning that protects
cardiac cells from iron-mediated oxidative damage associated
with ischemia-reperfusion injury [17]. However, almost 20
years ago it has been shown that liver ferritin can act both
as an antioxidant and a prooxidant in a time-dependent
manner. Oxidative stress caused by glutathione depletion
[18] or postischemic reperfusion [19] first induced ferritin
degradation and consequent LIP expansion that subsequently
activated ferritin expression, thus limiting the prooxidant
challenge of iron. A similar mechanism has been recently
described in the context ofmyocardial protection by ischemic
preconditioning; proteasomal ferritin degradation leads to
cytosolic iron release, thus triggering de novo apoferritin
synthesis and sequestration of reactive iron [20].
2.2. Altered Cardiac Iron Balance. Since under normal con-
ditions Tf-bound iron is not limiting, the uptake of iron
into the cells is controlled by the regulated expression of
TfR1 [21]. Therefore, iron overload is observed only when
the binding capacity of Tf is saturated and non-transferrin-
bound iron (NTBI) or labile plasma iron (LPI), the fraction
ofNTBI that is able to penetrate into the cells and is chelatable
[22], is formed. Although NTBI is clearly implicated in
tissue siderosis, how it enters the cell remains undefined,
largely because of the incomplete characterization of the iron
species involved, with variable composition under different
pathological conditions and changeable association with
macromolecules. NTBI has been claimed to be associated
with various plasma components, such as citrate, phosphates,
and proteins [23]. After extracellular reduction to ferrous iron
by a cell-surface reductase like Dcytb, NTBI enters into cells
mainly through divalent cation transporters such as DMT1
and ZIP14 [24, 25]. However, the pathway of NTBI uptake
by cardiomyocytes appears to be mainly mediated by Ca
channels, either L-type or T-type [26, 27].
Iron’s toxicity within cells arises from its capacity to catal-
yse the production of ROS that cause lipid peroxidation and
organelle damage [28], which leads to cell death and fibrosis
and ultimately impaired systolic and diastolic function. A
recent study in a mouse cardiomyocyte cell line showed
that L-type channels are the more important mediators of
iron uptake [29]. The import of ferrous iron by L-type
channels, with consequent higher ROS production, may
inhibit calcium influx, thereby affecting cardiac excitation-
contraction coupling that is highly sensitive to changes in
cellular redox state (reviewed by [30]). This in turn will
lead to the impaired systolic and diastolic function that is a
characteristic of iron-overload cardiomyopathy. Interestingly,
a recent paper showed that iron accumulation mediated by
the iron-binding protein Lipocalin-2 leads to cardiomyocyte
apoptosis and heart remodeling [31].
Exporting excess iron may represent a way to coun-
terbalance NTBI influx, and indeed it has been shown
that heart overload induces ferroportin mRNA levels in
hemojuvelin-deficient mice [32]. Similarly, marked upreg-
ulation of cardiomyocyte ferroportin in mice lacking hep-
cidin was protective against systemic iron overload [13]. In
many conditions leading to iron-mediated cardiomyopathy,
such as 𝛽 thalassemia, hepcidin levels are paradoxically low
despite the induction associated with body iron overload
because erythropoiesis-dependent downregulation prevails
[33]. Therefore, under these settings, low levels of circulating
hepcidin may concur with the transcriptional upregulation
[32] to enhance ferroportin expression and export activity,
thereby helping the heart avoid iron accumulation, at least
until a certain threshold is reached [34].
2.3. Iron- and Anthracycline-Induced Cardiotoxicity. Iron can
also play a relevant role in cardiotoxicity induced by other
agents, as in the case of anthracycline-dependent cardiotoxi-
city. Doxorubicin (DOX) belongs to the family of antitumor
anthracyclines that are among the most effective agents in
a number of neoplastic diseases. Unfortunately, the clinical
use of DOX is limited by the possible development of
cardiomyopathy and congestive heart failure. Given the tight
relationship between the amount of DOX accumulated in
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the heart and the incidence of cardiac events, the cumulative
dose of 500mg/m2 DOX should not be exceeded; respecting
this threshold reduces considerably the incidence of cardiac
events but can preclude successful completion of chemother-
apy [35].
Many observations indicate that iron plays a role in
DOX cardiotoxicity, such as the higher susceptibility to
DOX-dependent cardiac damage found in mice lacking
HFE, a model that mimics the iron overload found in
human hereditary hemochromatosis [36], and the associa-
tion of myocardial injury with the frequency of HFE gene
mutations in survivors of childhood acute lymphoblastic
leukemiawhowere exposed to anthracyclines [37].Moreover,
convincing evidence showed that iron chelation effectively
protects against cardiotoxicity in patients and animal models
[35]. While several studies demonstrated that iron overload
exacerbates the cardiotoxic effects of the drug, the underly-
ing molecular mechanisms remain to be fully understood.
Since anthracyclines degradation, by virtue of reductive
activation of the quinone moiety of DOX by a number
of reductases, eventually results in the formation of O
2
∙−
and H
2
O
2
, amplification of iron-catalyzed formation of free
radicals may represent an obvious mechanism at the basis
of the role of iron in DOX cardiotoxicity. However, while
anthracycline cardiotoxicity is relieved by iron chelators like
dexrazoxane, none of several antioxidants offered protection
against chronic cardiotoxicity in clinical settings [35, 38,
39]. How the interaction between anthracyclines and iron
damages heart cells is still unclear but may be mediated
not by DOX-iron interactions but by profound interference
with proteins of iron metabolism, thereby ultimately leading
to dysregulation of fundamental cellular events. The major
processes linking iron and anthracycline metabolism involve
ferritin and IRPs. We showed that DOX can inactivate both
IRPs, an event that disrupts cellular iron homeostasis, thereby
triggering serious pathologic consequences (reviewed in
[35]). Regarding ferritin, while initial in vitro experiments
suggested that ferritin may represent a source of catalytically
active iron released upon O
2
− formation [40], recent data
provided by in vivo studies indicate that ferritin synthesis
may rather be a defensive mechanism to limit the amount
of iron available for ROS production in the heart (reviewed
in [41]). Since it is well known that cardiac mitochondria
are preferential targets of anthracyclines, attention has been
recently focused on the role of mitochondrial ferritin (FtMt),
a recently identified ferritin type that accumulates specifically
in the mitochondria which, thanks to its ferroxidase activity,
actively sequesters iron and reduces iron-mediated oxidative
damage. Two recent papers highlighted the role of FtMt in
these settings: FtMt is induced in the heart of DOX-treated
mice [42] andhigher susceptibility toDOX-dependent oxida-
tive cardiac damage was found in FtMt-deficient mice [43].
These data, together with the recent demonstration that the
expression of ABCB8, which is involved in iron export out
of the mitochondria, is key to modulate heart sensitivity to
DOX [42], underline the importance of mitochondrial iron
availability for anthracycline cardiotoxicity.
The iron chelator dexrazoxane is the only agent protect-
ing against DOX cardiotoxicity; however, the mechanisms
underlying its protective role, whichmay include activation of
hypoxia inducible factor [44], remain to be fully established
[41]. A recent study showed beneficial effects of lovastatin
against DOX-induced delayed cardiotoxicity in mice [45].
Statin drugs have pleiotropic effects independent of their
capacity to lower cholesterol. In particular, it has been
shown that they influence the expression of proteins of iron
metabolism like heme oxygenase and hepcidin (discussed by
[46]). Further studies are needed to assess the usefulness of
statins for the prevention of iron-mediated cardiotoxicity.
2.4. Iron Maldistribution. Iron-mediated cell damage does
not occur only under conditions of systemic iron overload.
Indeed, recent evidence showed that iron maldistribution
among organs or tissues and also among cellular compart-
ments can affect cell integrity and life [47]. An example of
the first type of incorrect iron distribution is the retention
of iron in the reticuloendothelial system that is typically
observed under inflammatory conditions and contributes to
the development of anemia of chronic disease. On the other
hand, the heart is particularly affected by maldistribution
within cardiac cells.Mitochondria appear to be the organelles
primarily affected by subcellular regional iron accumulation,
and this fact, along with their high production of ROS, lays
the foundation for oxidative damage.Moreover, disruption of
iron homeostasis inmitochondriamay play a role in the ROS-
mediated mitochondrial decay that accompanies aging [10].
Mitochondrial iron levels are strictly controlled, as the dual
role of iron (necessary but dangerous) is particularly evident
in this organelle that is involved in heme synthesis and iron-
sulfur cluster assembly. This is in line with recent evidence
showing that iron is a pivotal regulator of mitochondrial
biogenesis [48].
Under iron overload conditions, iron accumulation in
mitochondria may be the result of very efficient and fast
iron transfer to these organelles. In fact, it has been demon-
strated that cardiac mitochondria rapidly acquire NTBI,
commonly present in the plasma of iron-loaded patients [49].
In mice injected with iron dextran, iron accumulation in the
heart was accompanied by damage to mitochondrial DNA
and impaired synthesis of mitochondrial respiratory chain
subunits, eventually leading to respiratory dysfunction and
cardiomyopathy [50]. Moreover, mitochondria-specific iron
overload can result from impaired utilization of iron for the
synthesis of heme, such as in sideroblastic anemia, or Fe-S
clusters, such as in Friedriech ataxia (FRDA) [51]. Defective
iron sulfur cluster biogenesis due to frataxin deficiency in
FRDA leads to mitochondrial iron accumulation by means
of still not fully understood mechanisms and is accompa-
nied by progressive cardiomyopathy [52]. Other conditions
characterized by alterations in different genes involved in Fe-
S cluster biogenesis are accompanied by mitochondrial iron
accumulation. Examples are the mutations in the scaffold
protein ISCU in Swedish myopathy or in the ABCB7 gene in
X-linked sideroblastic anemia with ataxia and the mutation
in glutaredoxin GLRX5 identified in a patient presenting
sideroblastic anemia (reviewed in [53]). Interestingly, recent
data (discussed in detail in [52]) seem to suggest that,
despite mitochondrial iron excess, the cell and the organelles
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may face iron deprivation, as the accumulated iron is not
biologically available.
Other pathogenetic mechanisms leading to mitochon-
drial iron accumulation may be related to defective export
or unregulated import.The ATP-binding cassette transporter
ABCB8 exports iron out of mitochondria and its absence
leads to mitochondrial iron accumulation, oxidative stress,
cardiomyopathy, and higher susceptibility to DOX-induced
cardiotoxicity [54]. In this context, recent findings indicate
a role for proteins belonging to the NEET family that are
involved in the transfer of cluster/iron to mitochondria.
NEET proteins influencemitochondrial iron levels and hence
may play an important role in the control of cellular iron
metabolism and ROS homeostasis [55].
The role of correct mitochondrial iron management is
highlighted by the existence of MtFt that readily sequesters
iron in these organelles (see above). By so doing, FtMt pro-
tects mitochondria against iron-dependent oxidative damage
and also modifies cellular iron distribution by attracting
iron from the cytosol to mitochondria [15]. FtMt is highly
expressed in the heart and protects cardiac mitochondria
against DOX-induced oxidative damage [43].
Reducing mitochondrial iron may protect the heart
through inhibition of oxidative stress. However, mitochon-
dria-targeted iron chelators should be used in order to avoid
(or not increase) systemic iron deficiency. This approach has
been already pursued, as mobilization and redistribution of
mitochondrial iron was reported with the use of deferiprone
[56] (see below).
2.5. Progression from Cardiomyocyte Injury to Heart Dis-
ease. Although production of hydroxyl radical and lipid
peroxidation are important in the initiation of iron-overload
cardiomyopathy, additional mechanisms involving apoptosis
and fibrosis can account for its complex pathophysiology that
leads to heart failure [27, 57, 58].
For example, it has been shown that thromboxane A2
mediates iron-overload cardiomyopathy through the TNF-𝛼-
associated calcineurin-NFAT signaling pathway [59]. Other
studies have identified the importance of proinflammatory
mediators, including TNF-𝛼, MCP-1, and IL-6, expressed
within the myocardium in response to high blood pres-
sure, oxidative stress, and tissue injury, resulting in car-
diac remodeling that includes cardiomyocyte apoptosis and
cardiac fibrosis (reviewed in [30]). These findings indicate
that macrophage-cardiomyocyte interactions play a key role
in cardiac inflammation and subsequent fibrosis found in
iron overload cardiomyopathy. Indeed, prolonged increase
in myocardial fibrotic activity results in stiffening of the
heart and is an indicator of adverse outcomes related to sys-
tolic and diastolic dysfunction, as well as arrhythmogenesis.
Regarding fibrosis, matrix metalloproteinases (MMPs), that
are important for pathophysiological tissue repair, appear
to be involved in cardiac remodeling. The finding that an
iron-binding protein like Lipocalin-2 is induced in a porcine
model of heart failure and associates with MMP-9 [60]
suggests that iron may also directly influence heart fibrotic
response.
3. Preclinical Animal Models of
Cardiac Iron Overload
Recent advances in understanding the pathophysiology of
iron-dependent cardiomyopathy have been made possible
also by the availability of animal models. Several studies used
parenteral iron administration in mice (see e.g., [61]), but
also in gerbils [62], to investigate cardiac iron overload and
damage. However, in this context the cellular distribution of
excess iron, which preferentially targets macrophages rather
than cardiomyocytes, does not closely reproduce human
heart pathology.
In addition to mouse models of 𝛽 thalassemia, which is
the secondary iron overload condition more closely linked to
cardiac iron overload [63], animal models involving ablation
of genes that are inactivated in hereditary hemochromatosis
also represent useful and validated models of body (and
heart) iron overload. Mouse models involving HFE [64],
hemojuvelin [32, 65], hepcidin [66], and transferrin receptor
2 (TfR2) [64] inactivation lead to iron loading phenotypes
ranging from mild to severe. Cardiac iron accumulation is
slower than hepatic iron loading, but, despite the more grad-
ual accumulation, heart iron levels and distribution in mice
lacking hemojuvelin are similar to humans. However, while
in human hemochromatosis long-term deposition of iron
in the heart can lead to cardiomyopathy, such pathological
consequence of iron overload is more difficult to obtain in
corresponding mouse models. Recently, it has been shown
that cardiomyocyte-targeted deletion of ferroportin leads
to increased cardiomyocyte iron deposition and severely
impaired cardiac function despite a moderate degree of iron
loading [13]. This study elegantly showed that the effects of
iron depend on the site of accumulation.
Despite the divergence in cardiac phenotypes induced by
iron overload in humans and mice, these models also proved
to be very useful to test novel therapeutic approaches to treat
cardiac iron overload (see below).
4. Clinical Conditions Involving
Cardiac Iron Overload
It is well recognized that systemic iron overload conditions,
in which the iron chelating capacity of our blood (i.e., Tf) is
exceeded, are associated with cardiomyopathy [67]. However,
it should be remarked that, in line with the idea that the
organism requires a balanced amount of iron, also iron
deficiency is frequently found in patients with heart failure
and represents a serious comorbidity associated with poor
clinical outcomes [68]. Cardiac iron overload is commonly
associated with hemochromatosis and disorders requiring
repeated blood transfusion (see below); however, the adverse
effects of iron overload are also found in patients undergoing
hematopoietic stem cell transplantation. In these settings,
NTBI formation occurs upon initiation of the conditioning
regimen until engraftment, due to the inhibition of iron
utilization by the erythroid compartment [69]. The clinical
dysfunctions of iron overload cardiomyopathy have been
excellently covered elsewhere [27] and will not be treated in
detail here.
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4.1. Primary Iron Overload. In HFE-linked hereditary
hemochromatosis patients, iron overload first affects the
liver, but cardiac problems (arrhythmias and heart failure)
are also found, although in a low percentage of cases [70]. In
addition, ventricular systolic function may be normal at rest
but compromised under exercise [71]. Moreover, in juvenile
hereditary hemochromatosis, which shows a more severe
phenotype, death from intractable heart failure is common
[72]. Diastolic dysfunction and arrhythmias that are present
initially can progress to dilated cardiomyopathy. Early
treatment (usually by phlebotomy) is effective but the average
survival is less than a year in untreated patients with severe
cardiac impairment [73]. Remarkably, the iron concentration
in the heart shows heterogeneous distribution and is signif-
icantly lower than in the liver, thus confirming the high sus-
ceptibility of cardiac cells to iron-mediated oxidative injury.
4.2. Secondary Iron Overload. Secondary iron overload is
mainly observed in association with transfusion-dependent
diseases [67, 74]. Because humans lack any effective means to
excrete excess iron, long-term transfusion alone inexorably
produces the clinical problem of iron overload in patients
needing repeated transfusion (e.g., thalassemia, Blackfan-
Diamond anemia, aplastic anemia, sideroblastic anemia, and
myelodysplasia). With continued transfusion, macrophages
and hepatocytes can no longer retain all the surplus iron
that then enters plasma in amounts that exceed the transport
capacity of circulating Tf, and NTBI develops. Transfusional
iron overload affects particularly patients with inherited
hemoglobinopathies, which are the most common single-
gene disorders in humans, as all thalassemia major patients
and 20% of those with sickle cell disease are transfusion-
dependent [75].
While the necessity of transfusion for severe anemia is
undisputed, it is clear that the risk of transfusion-dependent
iron overload should be carefully considered. Patients with
low-grade myelodysplasia who have sufficient longevity may
experience the deleterious effects of cardiac iron overload
that adversely impact survival in these patients. Treatment
with iron chelators (see below) avoids cardiac dysfunction in
these settings, although the beneficial effect of chelation in
preventing cardiac dysfunction may not be linked only to the
removal of excess tissue iron [76].
5. Detection of Cardiac Iron Overload
Several diagnostic methods have been developed in order to
detect myocardial iron overload as early as possible, thereby
averting a process that can lead to cardiomyopathy, heart fail-
ure, and ultimately death. These include evaluation of serum
ferritin levels, electrocardiography (ECG) echocardiography,
and cardiac magnetic resonance imaging T2∗ (cMRI-T2∗).
While ECG, echocardiography, and serum ferritin levels are
very easy and cheap methods, they are either not specific for
cardiac overload or not enough sensitive for the detection of
iron in the heart. Since iron is able to reduce the magnetic
resonance signal, the parameter called T2∗ measures the
amount of iron in heart as the loss of signal in iron-loaded
tissue. cMRI-T2∗, which is based on the evaluation of T2∗, is
the most efficient diagnostic technique for the evaluation of
cardiac iron overload [77, 78]. T2∗ values lower than 20ms
(physiological value) indicate presence of iron overload and,
as T2∗ changes according to the concentration of iron, values
lower than 10ms indicate the presence of severe iron overload
with high risk of developing cardiac dysfunctionwithin 1 year
[77, 79]. It should be pointed out that cMRI is an efficient
method also to evaluate the efficacy of iron chelator therapies.
In addition, the early detection of cardiac iron overload and
associated cardiac dysfunction by means of cMRI-T2∗ allows
more time for reversal through iron chelation therapy.
6. Treatment of Cardiac Iron Overload
The treatment of cardiac iron overload is mainly based on
the use of iron chelators. The majority of data regarding the
treatment of transfusional iron overload are derived from
the thalassemia population [80]. However, the use of iron
chelators resulted to be efficient in reducing iron overload and
improving survival also in transfusion-dependent patients
with myelodysplastic syndrome [76].
The chelators presently approved by EU and FDA for clin-
ical use include deferoxamine, deferiprone, and deferasirox
[81]. Introduction of deferoxamine 40 years ago dramatically
changed the cure and life expectancy of patients with cardiac
iron overload, in particular thalassemic patients. Long-term
therapy with deferoxamine is associated with a reduction
in cardiac complications and improved survival. However,
deferoxamine is a lipophobic molecule with limited capacity
to chelate intracellular iron and has several side effects.
Moreover, adherence to deferoxamine therapy is a challenge
because it has a short half-life and hence has to be usu-
ally administered by prolonged subcutaneous infusion [82].
Despite recent findings showing that new molecules may be
more effective for removing heart iron [83], deferoxamine is
still one of the most widely used iron chelators and is the
recommended first-line therapy for iron overload in people
with thalassaemia major [84].
The limits of deferoxamine prompted the search for
alternative drugs and two oral iron chelators, deferiprone and
deferasirox, are now commonly used.
Deferiprone is a lipophilic molecule with high chelating
capacity for intracellular iron that can be given orally and
it is quickly absorbed. These properties enable its prompt
entry into cells, including those of cardiac tissue [85]. Studies
have demonstrated reduced cardiac morbidity and mortality
and lower myocardial iron deposition among patients treated
with deferiprone. Side effects include reduced number of
neutrophils [86].
Also deferasirox is orally administered once a day, due
to its long half-life. It is a lipophilic, low molecular weight
molecule that is able to chelate intracellular iron as well as
iron in the blood, thereby preventing cardiac iron accumula-
tion. This effect was recently confirmed in the prospective,
multicentre study of deferasirox in transfusion-dependent
thalassemic patients with evidence of myocardial iron over-
load without cardiac dysfunction [87].
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Figure 1: Roles of iron in the pathologic progression leading to cardiac dysfunction. Excess iron, derived from either systemic overload (e.g.,
in thalassemia) or mislocalization (e.g., in FRDA), can directly catalyze ROS formation. Alternatively, iron may function as cofactor of other
damaging agents, such as the cardiotoxic drug doxorubicin, or events, like postischemic reperfusion, and amplify their oxidative-dependent
cardiotoxic effect. As described in the text, iron may also influence inflammatory events and repair processes, thereby fueling the progression
of cardiomyopathy. The possible therapeutic interventions are also highlighted.
The choice of the best therapy depends on the severity of
cardiac siderosis, the estimated total body iron burden, the
presence of organ dysfunction, and the rate of transfusion
therapy. Iron is accumulated in (and removed from) different
organs at different rates, and hepatic iron stores usually
change more rapidly than cardiac iron levels, so both hepatic
and cardiac iron must be measured to optimize chelation.
In addition, a recent study showed that deferiprone has
greater efficacy in removingmyocardial iron burden, whereas
deferoxamine was particularly effective against liver iron
deposition [83].
Wewill not address here the extensive literature regarding
the clinical efficacy of the different chelating therapies using
the various chelators, either alone or in combination (see
[86] for a review). However, we will briefly examine the
chelating properties of the various molecules in relation to
their susceptibility towards redox cycling.
Tomaximize the thermodynamic stability of the iron(III)
ligand complex, all the six iron atoms should be bound
to donor atoms of the chelator to form a stable inert
complex. Ligands can be structurally classified according to
the number of donor atoms that each molecule possesses,
that is, bidentate (e.g., deferiprone, least stable), tridentate
(e.g., deferasirox), and hexadentate (e.g., deferoxamine, most
stable). Low stability increases the risk of the participation
of incomplete iron-chelate complexes in the generation of
harmful free radicals. As a consequence, only with dosages
high enough (>10 𝜇M) to reach a 3 : 1 molar ratio of biden-
tate chelator to iron, stable iron-coordinate complexes and
efficient and safe scavenging of excess iron will be achieved
[88, 89]. Interestingly, this capacity of the iron-deferiprone
complex to donate iron to competing ligands at relatively low
concentrations has been exploited to develop combination
therapies in which deferiprone is used together with a high
affinity hexadentate chelator such as deferoxamine. In this
context, the deferiprone-iron complex will readily donate
iron to the kinetically more stable deferoxamine (shuttle
effect) [90]. Clinical studies indicated that such approach
minimized side effects (by virtue of lower doses) and was
effective at increasing iron removal and survival. An excellent
overview of combination iron chelation therapy has been
presented [91].
Given the role of L-type and T-type Ca channels in iron
import into cardiomyocytes (see above), calcium channel
blockers were considered for cardiac iron overload treatment.
The L-type calcium channel blockers amlodipine and vera-
pamil proved to be effective in treating heart iron overload
in a validated mouse model [92, 93] and the T-type calcium
blocker efonidipine improved cardiac function in a mouse
model of thalassemia [94]. Remarkably, amlodipine was
successfully used in patients [95, 96].
In view of the role of oxidative damage in cardiac
iron overload, another potential therapy is represented by
antioxidants. Indeed, it has been demonstrated that taurine
supplementation reduced oxidative stress in the heart of
iron overloaded mice, thereby preserving cardiovascular
function and improving survival [57]. In line with the tight
relationship between iron and oxidative stress, iron chelators
and prochelators are presently considered for their capacity
to protect cardiac cells against injury induced by ROS [97].
7. Conclusions
The role of iron in the pathogenesis of cardiac damage
is undisputed, but the underlying molecular mechanisms
remain incompletely understood. However, it is possible to
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anticipate that our increased understanding of the regula-
tory network that controls iron homeostasis may lead to
a better management of cardiac iron overload. The studies
highlighted in this review have shown that the role of iron can
bemanifold.While early studies pointed to a role as amplifier
of the free radical generation initiated by redox cycling,
more recent evidence suggests that the cardiotoxic role of
iron should not be restricted to the oxidative stress scenario.
Iron can act in concert with other damaging agents or
events and amplify their cardiotoxic effect (Figure 1). Another
important aspect is the site of iron accumulation, both
among different heart cells and within the cardiomyocyte,
as not only iron overload but also mislocalization can lead
to cardiomyopathy. Defects in iron handling (particularly in
the mitochondria) may contribute to heart damage through
ROS-mediated mechanisms but also through disruption of
Fe/S cluster and/or heme synthesis. Moreover, iron not only
can play a role in cardiomyocyte damage but also influ-
ence the mechanisms leading to the progression of cardiac
dysfunction, as iron-dependent expression of macrophage-
derived inflammatory mediators may influence fibrosis and
the progression of cardiomyopathy. Exploring more deeply
the pathogenicmechanisms of iron overload cardiomyopathy
will reveal useful insights for the development of novel
therapeutic strategies.
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